8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
INCYTE CORP (INCY)

Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…

Filed with the SEC on · Summarized by InvestorsBot

Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page Interactive XBRL also filed (Exhibit 104). $INCY 📄🔎 #8K #Incyte #Biotech

The 8‑K was signed Feb 10, 2026 by Thomas Tray (VP & Principal Financial/Accounting Officer). Investors should read the attached press release for any material disclosures. $INCY 🕒📢 #8K #Investing

Item 9.01 lists only exhibits (99.1 press release; 104 XBRL) — no new financial statements or pro forma info included in this filing. $INCY 📑✅ #SEC #Biotech

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from INCYTE CORP

Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…

8-K · March 26, 2026

Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.

8-K · March 26, 2026

FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…

8-K · March 6, 2026

Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY…

8-K · February 10, 2026

Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025.

8-K · December 12, 2025